Connect with us


Top 5 Stocks Under $10

WASHINGTON – MARCH 2: An uncut sheet of the redesigned $10 bill is seen after a news conference to commemorate the first day of circulation of the new notes at the National Archives March 2, 2006 in Washington, DC. The new $10 note is the latest issue in the new series of U.S. currency, with features including color-shifting ink, watermark and security thread which are easy to check by naked eye. (Photo by Alex Wong/Getty Images)

Back in April, we wrote on article on top stocks under $10. This proved to be a very rewarding experience. We are re-introducing an old concept of buying stocks below a $10 stock price. Typically, it is hard to find companies possessing the collective financial traits we seek, such as the attractive characteristics of value, growth, strong EPS revisions, profitability and strong momentum. Fortunately, the power of filtering big data along with our systematic trading model has helped CressCap to identify five stocks under $10 that possess the above core fundamental metrics which we desire.

The foundation of our recommendations is to identify companies that perform best and worst on the collective basis of value, growth, EPS revisions, profitability, and LT momentum. The CressCap systematic trading model gathers data daily on 6,500 companies globally and assigns academic grades (A – F) for each financial metric. These grades are scored relative to its region/sector.

Expand to see how our directional recommendations are computed: CressCap uses a multi-factor model to select the best-performing stocks. Our data is updated daily and the academic grades (A – F) for each financial metric are scored and ranked on a regional/sector relative basis. The foundation of our recommendations is to identify companies that possess the collective investment style of Value, Growth, EPS Revisions, Profitability and LT Momentum. Academic grades of C or better indicate that each metric scores well compared to the peer sectorCRESSCAP INVESTMENT RESEARCH

Cerus Corporation (CERS-US)

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. This is a standout stock in the healthcare sector, given a rank of 26 out of 365 companies. Its positive performance can be seen over the last 52 weeks with the price increasing by 165.74%. This stock has a CressCap grade of A+ and a buy recommendation. The long term price momentum looks favorable for the company, far outperforming the sector at 156.10% to 17.86% accompanied with an A+ grade. The EPS revisions are encouraging for Cerus with the stock outperforming the sector with an A rank. William ‘Obi’ Greenman, Cerus’ president and chief executive officer is very optimistic about the company’s future. In the 2018 quarter one results, he stated product revenue for the first quarter of 2018 was $13.6 million, compared to $7.0 million during the same period in 2017. This is a growing company, and the stock is a good place to put your money.


Costamare Inc. (CMRE-US)

Costamare Inc. is one of the world’s leading owners and providers of containerships for charter. The Company has 44 years of history in the international shipping industry and a fleet of 73 containerships. The stock is recommended as a buy based on our quant model and is also supported by technical indicators and fundamental analysis. The stock offers great value compared to its competitors in the industrial sector, with EV/EBITDA of 6.64 relative to a sector ratio of 11.82 and a CressCap P/B and P/CF grade of A+. Profitability for this stock looks strong, with both the operating and EBIT margin outperforming the sector at 64.56 to 14.65 and 39.32 to 9.19 respectively. The short, mid and long-term price momentums are impressive for the stock, each receiving a CressCap grade of A or better.

DHT Holdings, Inc. (DHT-US)

Our next recommendation with a price under $10 is DHT Holdings. Double Hull Tankers, Inc. is an independent crude oil tanker company, whose fleet trades internationally and consists of crude oil tankers in the VLCC and Aframax segments. All five metrics of value, growth, EPS revisions, profitability and momentum have a CressCap rank of B- or above, showing us that this is a favorable stock in the industrials sector. The 2 year forward EPS growth rate of this stock is crushing the sector at 435.89% to that of the sector at 30.99%. The P/B ratio of this stock at 0.72x compared to the sector 2.49x which shows that the stock is undervalued. Both the short and mid term price momentum are given an A+ grade, reinforcing the positive momentum of this growing company. The outlook on the stock is favorable, with its YTD performance up 30.50%. We view this stock as a good opportunity for under $10.

MEI Pharma, Inc. (MEIP-US)

MEI Pharma, Inc. is a San Diego-based oncology drug development company with a pipeline of three clinical-stage drug candidates and a management team with proven oncology drug development experience. This company has a regional universe rank of 53 out of 1,928 companies and a healthcare sector rank 8 out of 365 companies. The stock is recommended as a buy based on our quant model and is also supported by technical indicators and fundamental analysis. A market cap change of 213.97% relative to a sector change of 33.87%, means the momentum of the stock shows promise. The P/B ratio of 2.85 beats sector performance of 5.25, which suggests that the stock is of good value. As of March 31, 2018, the company had $36.2 million in cash, cash equivalents and short-term investments, with no outstanding debt. This company has strong financial metrics, and should be seen as an investment opportunity to investors.


R1 RCM Inc is the last company on our list. R1 RCM Inc is a leading provider of revenue cycle services and physician advisory services to healthcare providers. This Chicago based company is seen as a solid choice for investors looking to put their money in stocks less than $10. In first quarter 2018 results, the company reported that they generated net services revenue of $147.3 million, up $60.4 million compared to the same period last year. This stock is seen as having good value while trading cheaply with a P/S ratio of 1.97 compared to that of the sector at 6.99, given an A- CressCap grade. Another strength of this stock is its momentum, standing out in the healthcare sector with both mid and long term price momentum given a Cresscap grade of A. The price change also looks favorable, with it increasing 131.47% in the past 52 weeks.






This financial news and information portal (, and/or our newsletters contain commercial advertisements, and are for general entertainment purposes only. Along with the aggregation of timely financial news, we are engaged in the business of analyzing, marketing and advertising companies for monetary compensation. Unless otherwise stated below, the paying Third Party for our services may own shares and may liquidate them during any and all advertising periods. This disclaimer is to be read and fully understood before using, or joining one of our newsletter lists. We also encourage you to read the SEC INVESTOR ALERT before reading content found on and/or our newsletters. You are reading content found on our financial news and informational portal because you have clicked on an advertisement found on one of many marketing channels we advertise on. is for entertainment purposes only. We are NOT a source of unbiased information. Never invest in any stock featured on our site or newsletters unless you can afford to lose your entire investment. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled on the website/newsletter and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead, strongly urges you to supplement the information obtained from this website/newsletter with a complete and independent investigation of the companies discussed and a consideration of all pertinent risks. Investing in securities, including the securities of the companies profiled or discussed on this website/newsletter, is highly speculative and carries a high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies discussed. The information found on, and/or our newsletters are based on sources, which we believe to be reliable, but are not guaranteed by us as being accurate and do not purport to be a complete statement or summary of the available data. encourages readers and investors to supplement the information found on our site or in our newsletters with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources. makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the featured companies None of the owners of, or any of its directors, officers, employees, contractors, or affiliates is a licensed broker-dealer, account representative, market maker, investment banker, investment advisor, analyst or underwriter in any jurisdiction whatsoever. does not offer such advice or analysis, and further urges you to consult your own independent tax, business, financial and investment advisors before purchasing or selling any securities of the companies discussed on this website/newsletter. Compensation: has not been compensated for marketing and advertising services. does not own any shares of any featured company. Whoa Is Media, Inc. may own shares and may sell all, any or none of any shares held in any featured company during advertisement periods, which may negatively affect the featured company’s stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the featured company. and its employees, contractors, officers, directors, or affiliates may purchase shares on the open market of any mentioned featured company during advertisement periods and following the dissemination of any newsletters. This is an inherent conflict of interest. The services provided by this website/newsletter and its contents are provided “as is” and makes no representations or warranties of any kind with respect to this website/newsletter, its contents or its services. This website/newsletter has been prepared solely for the purpose of providing information about and the services it offers. This website/newsletter has been compiled in good faith by assumes no liability or responsibility for any errors or omissions in the content of this website/newsletter, any failures, delays, or interruptions in its services or any content contained on this website/newsletter, any losses or damages arising from the use of the content provided on this website/newsletter, or any conduct by users of’s services. reserves the right to add, modify or delete any information at this website/newsletter at any time. This website/newsletter may contain “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that includes everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made in this report. Further specific financial information, filings, and disclosures as well as general investor information about the profiled companies, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website and the Financial Industry Regulatory Authority (“FINRA”) website at undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise. In addition to information about the company discussed, from time to time, this website/newsletter may contain the symbols of companies and/or news feeds or links to websites about companies that are not being discussed by us but are merely illustrative of certain activity in the stock market that we are highlighting (so-called hyperlinks to third party websites or access to third party content). Readers are advised that all links and access to these sites and content solely for informational purposes., its owners, directors, officers, employees, affiliates, and contractors are not responsible for errors and omissions nor does control, endorse, or guarantee any content found in such sites or content. Any opinions expressed are subject to change without notice. It is also possible that the companies discussed on those sites may not have approved certain or any statements within the report. By accessing or viewing this website/newsletter, you agree that, its owners, directors, officers, employees, affiliates and contractors are not responsible for any content, associated links, resources, or services associated with a third-party website. uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. In no event shall, its owners, directors, officers, employees, affiliates and contractors be liable (jointly or severally) for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with this website/newsletter. You agree to hold, its owners, directors, officers, employees, affiliates and contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of the information contained on this website/newsletter (including any loss or damage of any sort associated with your use of third party content). You agree that use of this website/newsletter is at your sole risk. disclaims all warranties of any kind, express or implied. If any applicable authority holds any portion of this section to be unenforceable, then liability will be limited to the fullest possible extent permitted by applicable law. encourages readers to invest carefully, and read investor and issuer information available at the websites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at and filings made by public companies can be viewed at . In addition, FINRA has published information at its website on how to invest carefully at Questions regarding any information contained on this website/newsletter may be sent to To review’s website and its disclaimer, please visit

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

About Money News National

Money News National captures conversations around what Millennials are investing and wanting to invest in while highlighting trending stories around companies popular among millennials.

Are you on Facebook?

Want to join the online money news investor conversation? Join the private group of modern investors to connect, share, learn, and earn with today’s Millennial Investor.

Connect with us

Copyright © 2018 Money News National.